Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience

The adoption of neoadjuvant chemotherapy (NACT) for breast cancer (BC) is increasing. The need to repeat the biomarkers on a residual tumor after NACT is still a matter of debate. We verified estrogen receptors (ER), progesterone receptors (PR), Ki67 and human epidermal growth factor receptor 2 (HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Coiro, Saverio, Gasparini, Elisa, Falco, Giuseppe, Santandrea, Giacomo, Foroni, Moira, Besutti, Giulia, Iotti, Valentina, Di Cicilia, Roberto, Foroni, Monica, Mele, Simone, Ferrari, Guglielmo, Bisagni, Giancarlo, Ragazzi, Moira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700750/
https://www.ncbi.nlm.nih.gov/pubmed/34943486
http://dx.doi.org/10.3390/diagnostics11122249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700750/
https://www.ncbi.nlm.nih.gov/pubmed/34943486
http://dx.doi.org/10.3390/diagnostics11122249

Ejemplares similares